Kidney Cancer Articles & Analysis
41 news found
” Now hospitals can use the technology while we learn more about the long term (>10 years) outcomes of using the NanoKnife System for prostate cancer as they collect their audit data. When men are diagnosed with prostate cancer it is graded as Low, Intermediate or High risk. ...
Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, gastric, prostate, pancreatic, liver, and kidney cancers. He also discusses several of the company’s near-term pipeline products and other areas of possible ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 ...
Cancer Research Communications is an open access peer-reviewed journal published by the American Association for Cancer Research. ...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today it has entered into a Royalty Interest Purchase and Sale Agreement (the agreement) with HealthCare Royalty Partners (HealthCare Royalty). Clearside intends to use the proceeds from the agreement to ...
Yair Halpern of Bnei Zion Medical Center, Haifa, Israel on renal cancer cryoablation and from Dr. Ghizlane Touimi Benjelloun of CHU de Nîmes, France on cryoablation of adrenal gland and vertebral metastasis. Scientific Presentation: Cryoablation of Low-Risk Breast Cancer An Update of the ICE3 Trial Dr. Kenneth R. Tomkovich, Co-Primary Investigator of the ...
In partnering with Promaxo, we are bringing minimally invasive, office based MRI to Beverly Hills, California, with a clinical focus on MR guided biopsies and treatments such as high intensity focused ultrasound (HIFU) of the prostate cancer.” “We continue to build upon our growing network of physician practices and are pleased to collaborate with Beverly Hills ...
The meeting includes state-of-the-art translational topics on prostate, kidney, and bladder cancer, as well as strategies in urologic oncology will be discussed. ...
” Tweet this “To our knowledge, this is the first randomized clinical trial to demonstrate that a live bacterial product can modulate the gastrointestinal microbiome and enhance immunotherapy response in cancer patients. These results can help improve treatment options for patients with kidney cancer and is an important foundational ...
Combined use of a VEGF tyrosine kinase inhibitor (TKI) and checkpoint inhibitor is already standard of care in advanced kidney, cervical and endometrial cancers. There has been suggestion that such a combination may have clinical activity in some microsatellite stable (MSS) GI malignancies. ...
AVEO plans to initiate a Phase 1b clinical trial in cancer patients in mid-2022. AV-203 Update During 2021, AVEO regained worldwide rights to AV-203. ...
“Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving way for our $3 billion addressable market for in-office prostate procedures. We are thrilled to welcome Kasraeian Urology to our growing network of physician practices and look forward to our partnership to improve ...
” About IceCure Medical Founded in 2006, Israel-based IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. ...
(NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. ...
Alpha-1 Biologics, a biotherapeutics company developing innovative treatments for cancers and immune deficiencies, today announced that positive data was published in frontiers in Oncology demonstrating Alphataxin, a small molecule that elevates circulating and tumor-infiltrating CD4+ T cells, suppressed kidney cancer and suppressed metastasis in ...
This is an important inflection point for the company as we work towards establishing a regulatory path to make the ProSense System available in other major markets, such as the United States, China, and Japan as a minimally invasive treatment to early-stage breast cancer patients. I look forward to supporting existing and new employees so that we may meet the significant market ...
(NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in ...
There are currently 8 companies in the portfolio providing game changing diagnostics in Alzheimer’s diagnosis, kidney health, breast cancer, mental health, maternal health, patient monitoring and multi cancer screening. ...
“The Polish healthcare system is known for providing advanced cancer treatment and adopting new therapies and technologies. As breast cancer continues to be one of the most common types of cancer among Polish women, with a reported 24,644 women diagnosed in 20201, Poland has joined the global effort to increase breast ...